Anti-clotting drug apixaban wins FDA approval

Bristol-Myers Squibb and Pfizer's apixaban has been approved by the FDA to reduce the risk of strokes and blood clots for people with atrial fibrillation. The anticoagulant, however, should not be given to patients with artificial heart valves or those with atrial fibrillation due to heart valve problems, the FDA said. The drug has been approved in Europe.

View Full Article in:

New York Times (tiered subscription model), The · USA Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC